Explore the words cloud of the Colodetect project. It provides you a very rough idea of what is the project "Colodetect" about.
The following table provides information about the project.
PROTEIN ALTERNATIVES SL
|Coordinator Country||Spain [ES]|
|Total cost||2˙490˙072 €|
|EC max contribution||2˙309˙447 € (93%)|
1. H2020-EU.3.1.3. (Treating and managing disease)
|Duration (year-month-day)||from 2015-10-01 to 2019-03-31|
Take a look of project's partnership.
|1||PROTEIN ALTERNATIVES SL||ES (Pozuelo de Alarcon)||coordinator||2˙309˙447.00|
A recent epidemiology of colorectal cancer (CRC) report demonstrated a significant CRC burden in European countries, which is still associated with very high mortality rates. The overall objective of the project is the development and commercialization of a test for the early detection of CRC based on the detection and measurement of cancer-specific autoantibodies present in blood of patients. The outlined test will detect simultaneously the presence in serum/plasma samples from CRC patients of specific autoantibodies (biomarkers) against a reduced number of tumor antigens (8-10). To reach this objective, several technological challenges have to be overcome, like to improve the sensitivity and detection limit in the early stages of CRC avoiding the obvious limitations provided by the invasive detection techniques extensively used, as the colonoscopy, and offering additional advantages compared to traditional CRC diagnostic methods, such the simplicity in applications, detection, accuracy and a reduced cost. The assay for the detection of CRC will be established and validated with clinical samples and tested for their marketability, to finally overtake the regulatory process to obtain the CE marking. The results obtained in this project will have extensive impact and benefits for European population at risk, since early detection programs are essential to decrease mortality around 30-35% and drastically reduce the treatment costs of people affected by the pathology, assuring the sustainability of the European healthcare systems and others in the world. The main objective of this project is to obtain a colorectal cancer diagnostic kit clinically validated and regulatory approved as an in vitro diagnostic product (IVD), and as well, to penetrate in the CRC diagnostic market allowing ProAlt to reach a competitive position by improving its competitiveness.
|Short video||Websites, patent fillings, videos etc.||2019-07-23 15:23:45|
|Final report on dissemination materials||Websites, patent fillings, videos etc.||2019-07-23 15:23:46|
|ColoDetect brochure||Websites, patent fillings, videos etc.||2019-05-30 11:39:11|
|ColoDetect Website||Websites, patent fillings, videos etc.||2019-05-30 11:39:03|
|Final Dissemination and Communication Plan||Websites, patent fillings, videos etc.||2019-05-30 11:39:13|
|First report on dissemination materials||Websites, patent fillings, videos etc.||2019-05-30 11:39:08|
|1st Dissemination and Communication Plan||Websites, patent fillings, videos etc.||2019-05-30 11:39:10|
|Informational ColoDetect factsheet||Websites, patent fillings, videos etc.||2019-05-30 11:39:09|
Take a look to the deliverables list in detail: detailed list of Colodetect deliverables.
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "COLODETECT" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (firstname.lastname@example.org) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "COLODETECT" are provided by the European Opendata Portal: CORDIS opendata.
PanCareFollowUp: Novel, patient-centred survivorship care to improve care quality, effectiveness, cost-effectiveness and accessibility for survivors and caregiversRead More
CeLac and European consortium for a personalized medicine approach to Gastric CancerRead More
ENDOSCAPE, a clinically applicable non-viral gene delivery technologyRead More